Logo image of VERA

VERA THERAPEUTICS INC (VERA) Stock Fundamental Analysis

NASDAQ:VERA - Nasdaq - US92337R1014 - Common Stock - Currency: USD

38.07  +1.53 (+4.19%)

After market: 38.5085 +0.44 (+1.15%)

Fundamental Rating

2

VERA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. While VERA seems to be doing ok healthwise, there are quite some concerns on its profitability. VERA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year VERA has reported negative net income.
In the past year VERA has reported a negative cash flow from operations.
In the past 5 years VERA always reported negative net income.
In the past 5 years VERA always reported negative operating cash flow.
VERA Yearly Net Income VS EBIT VS OCF VS FCFVERA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

VERA's Return On Assets of -36.46% is in line compared to the rest of the industry. VERA outperforms 60.00% of its industry peers.
VERA has a Return On Equity of -46.49%. This is in the better half of the industry: VERA outperforms 68.50% of its industry peers.
Industry RankSector Rank
ROA -36.46%
ROE -46.49%
ROIC N/A
ROA(3y)-53.81%
ROA(5y)-95.74%
ROE(3y)-85.69%
ROE(5y)-140.41%
ROIC(3y)N/A
ROIC(5y)N/A
VERA Yearly ROA, ROE, ROICVERA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for VERA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VERA Yearly Profit, Operating, Gross MarginsVERA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023

More info and screens

4

2. Health

2.1 Basic Checks

The number of shares outstanding for VERA has been increased compared to 1 year ago.
VERA has a worse debt/assets ratio than last year.
VERA Yearly Shares OutstandingVERA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 10M 20M 30M 40M
VERA Yearly Total Debt VS Total AssetsVERA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

VERA has a Debt/Equity ratio of 0.17. This is a healthy value indicating a solid balance between debt and equity.
VERA has a worse Debt to Equity ratio (0.17) than 69.38% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.17
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACCN/A
VERA Yearly LT Debt VS Equity VS FCFVERA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 50M -50M 100M

2.3 Liquidity

VERA has a Current Ratio of 13.76. This indicates that VERA is financially healthy and has no problem in meeting its short term obligations.
VERA's Current ratio of 13.76 is amongst the best of the industry. VERA outperforms 87.61% of its industry peers.
VERA has a Quick Ratio of 13.76. This indicates that VERA is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of VERA (13.76) is better than 87.61% of its industry peers.
Industry RankSector Rank
Current Ratio 13.76
Quick Ratio 13.76
VERA Yearly Current Assets VS Current LiabilitesVERA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 9.00% over the past year.
EPS 1Y (TTM)9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-88.89%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 31.07% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-25.52%
EPS Next 2Y-18.17%
EPS Next 3Y-9.87%
EPS Next 5Y31.07%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
VERA Yearly Revenue VS EstimatesVERA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
VERA Yearly EPS VS EstimatesVERA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 10 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

VERA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year VERA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VERA Price Earnings VS Forward Price EarningsVERA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VERA Per share dataVERA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

A cheap valuation may be justified as VERA's earnings are expected to decrease with -9.87% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-18.17%
EPS Next 3Y-9.87%

More info and screens

0

5. Dividend

5.1 Amount

VERA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VERA THERAPEUTICS INC

NASDAQ:VERA (2/4/2025, 8:14:07 PM)

After market: 38.5085 +0.44 (+1.15%)

38.07

+1.53 (+4.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)N/A N/A
Inst Owners107.09%
Inst Owner Change0.58%
Ins Owners2.99%
Ins Owner Change0.97%
Market Cap2.41B
Analysts83.33
Price Target68.68 (80.4%)
Short Float %12.52%
Short Ratio11.6
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-17.62%
Min EPS beat(2)-26.69%
Max EPS beat(2)-8.54%
EPS beat(4)0
Avg EPS beat(4)-13.67%
Min EPS beat(4)-26.69%
Max EPS beat(4)-3.59%
EPS beat(8)2
Avg EPS beat(8)-7.54%
EPS beat(12)3
Avg EPS beat(12)-10.79%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.26%
PT rev (3m)13.77%
EPS NQ rev (1m)2.67%
EPS NQ rev (3m)-41.27%
EPS NY rev (1m)-0.55%
EPS NY rev (3m)-11.19%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 8.34
P/tB 8.34
EV/EBITDA N/A
EPS(TTM)-2.63
EYN/A
EPS(NY)-3.23
Fwd EYN/A
FCF(TTM)-1.91
FCFYN/A
OCF(TTM)-1.91
OCFYN/A
SpSN/A
BVpS4.57
TBVpS4.57
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -36.46%
ROE -46.49%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-53.81%
ROA(5y)-95.74%
ROE(3y)-85.69%
ROE(5y)-140.41%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset TurnoverN/A
Health
Industry RankSector Rank
Debt/Equity 0.17
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.76
Quick Ratio 13.76
Altman-Z N/A
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-88.89%
EPS Next Y-25.52%
EPS Next 2Y-18.17%
EPS Next 3Y-9.87%
EPS Next 5Y31.07%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-33.82%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-65.87%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-108.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-128.18%
OCF growth 3YN/A
OCF growth 5YN/A